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Abstract
Background: Insulin-like growth factor 1 receptor (IGF1R) targeted therapies have resulted in responses in a small number
of patients with advanced metastatic Ewing’s sarcoma. We performed morphoproteomic profiling to better understand
response/resistance mechanisms of Ewing’s sarcoma to IGF1R inhibitor-based therapy.
Methodology/Principal Findings: This pilot study assessed two patients with advanced Ewing’s sarcoma treated with IGF1R
antibody alone followed by combined IGF1R inhibitor plus mammalian target of rapamycin (mTOR) inhibitor treatment
once resistance to single-agent IGF1R inhibitor developed. Immunohistochemical probes were applied to detect p-mTOR
(Ser2448), p-Akt (Ser473), p-ERK1/2 (Thr202/Tyr204), nestin, and p-STAT3 (Tyr 705) in the original and recurrent tumor. The
initial remarkable radiographic responses to IGF1R-antibody therapy was followed by resistance and then response to
combined IGF1R plus mTOR inhibitor therapy in both patients, and then resistance to the combination regimen in one
patient. In patient 1, upregulation of p-Akt and p-mTOR in the tumor that relapsed after initial response to IGF1R antibody
might explain the resistance that developed, and the subsequent response to combined IGF1R plus mTOR inhibitor therapy.
In patient 2, upregulation of mTOR was seen in the primary tumor, perhaps explaining the initial response to the IGF1R and
mTOR inhibitor combination, while the resistant tumor that emerged showed activation of the ERK pathway as well.
Conclusion/Significance: Morphoproteomic analysis revealed that the mTOR pathway was activated in these two patients
with advanced Ewing’s sarcoma who showed response to combined IGF1R and mTOR inhibition, and the ERK pathway in
the patient in whom resistance to this combination emerged. Our pilot results suggests that morphoproteomic assessment
of signaling pathway activation in Ewing’s sarcoma merits further investigation as a guide to understanding response and
resistance signatures.
Citation: Subbiah V, Naing A, Brown RE, Chen H, Doyle L, et al. (2011) Targeted Morphoproteomic Profiling of Ewing’s Sarcoma Treated with Insulin-Like Growth
Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures. PLoS ONE 6(4): e18424. doi:10.1371/journal.pone.0018424
Editor: Benjamin Edward Rich, Dana-Farber Cancer Institute, United States of America
Received November 4, 2010; Accepted March 5, 2011; Published April 6, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This study was funded by in part by U01 CA062461-17 (RK) and NCI-CTEP R21-CA13763301A1 (AN). This work was also supported by Grant RR024148
from the National Center for Research Resources (NCRR), National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the
responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/.
Information on Reengineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp. The
University of Texas MD Anderson Cancer Center is supported in part by the NIH through Cancer Center Support Grant no. CA 016672. Presented in part as a
platform presentation at the 16th Annual Meeting of the Connective Tissue Oncologic Society, November 11-13, 2010, Paris, France. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vsubbiah@mdanderson.org
Introduction
Ewing’s sarcoma is the second most common malignant bone
tumor in children, adolescents and young adults. Despite using a
multimodal approach combining surgery, chemotherapy, and
radiation, a therapeutic plateau has been attained with no
change in overall survival [1,2,3,4,5]. Attempts to improve
clinical outcome through collaborative trials beginning in the
early 1970s sought to optimize care through ever more
mechanistically-diverse chemotherapies. Strategies included
increasing duration of treatment or dosage per cycle, decreasing
treatment interval (i.e., interval dose compression), or using high-
dose myeloablative chemotherapy followed by peripheral blood
stem cell transplant [3]. However, survival remains poor for
patients with metastatic disease. For metastatic Ewing’s sarcoma
at diagnosis, the risk of refractory or recurrent disease
approaches 80% after initial therapy and the outcome of
recurrent disease is poor with event-free survival less than 20%
[3]. Treatment options for patients with refractory or recurrent
Ewing’s sarcoma are limited.
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18424Early phase clinical trials frequently combine targeted agents to
optimize benefit. Two challenges at the outset are 1) deciding
which agents to combine given the heterogeneity of tumors and
their various underlying resistance pathways and feedback loops,
and 2) how to translate findings from the bench to the bedside or
directly from the bedside [6]. Morphoproteomics (morphology+
proteomics) involves immunohistochemical assessment of the
activation of signaling pathways in cancer cells, and predicting
susceptibility to small-molecule inhibitors, specific chemothera-
peutic agents, and possibly, differentiating agents [7]. In some
cases, drugs that fail early in the disease trajectory can produce
renewed tumor regression later, particularly with rational addition
of another drug [8]. Morphoproteomics can potentially identify
targeted combinations of drugs appropriate for prospective testing
[9].
Insulin-like growth factor 1 receptor (IGF1R)-targeted therapies
have shown early promise [10], with responses in a small number
of patients with Ewing’s sarcoma [4,11,12,13]. Currently available
IGF1R antibodies recognize different epitopes of the receptor and,
therefore, may exert different biological/clinical responses [14,15].
Even so, phase I studies with different IGF1R antibodies
demonstrated remarkable responses in a subset of Ewing’s
sarcoma patients [11,12,13]. While response rates in Phase II
studies have not yet been reported, it is clear that while some
responses have been dramatic, they occurred in only a minority of
patients. The mechanisms underlying primary and secondary
response and resistance are unknown.
Herein, we report our experience with two index cases of
Ewing’s sarcoma, with an initial positive response to an IGF1R
inhibitor followed by resistance. Both patients subsequently
responded to a combination of an IGF1R inhibitor and a
mammalian target of rapamycin (mTOR) inhibitor. We per-
formed morphoproteomic profiling to elucidate the functional
signaling pathways in both patients.
Methods
Patient Selection, Treatment and Clinical Assessments
We reviewed the medical records of two patients with Ewing’s
sarcoma who were seen in the Phase I Clinical Trials Program at
The University of Texas MD Anderson Cancer Center and
initially treated with an IGF1R inhibitor alone, then subsequently
with an IGF1R and mTOR inhibitor combination. The patients
in this manuscript have given written informed consent (as
outlined in the PLoS consent form) to publication of their clinical
details. Treatment and consent on investigational trials, and data
collection and morphoproteomic analysis were performed in
accordance with the guidelines of the University of Texas MD
Anderson Cancer Center Institutional Review Board (IRB).
The patients in the manuscript were derived from two different
Phase I studies and a Phase II study using different IGF1R
inhibitors and all the studies have been registered in www.
clinicaltrials.gov. The scope of the studies, current status and
clinical trial registration identifiers are as follows:
1. A Multiple Ascending Dose Study of R1507 in Patients with
Advanced Solid Tumors (now closed and not actively recruiting
patients) NCT00400361 (Phase I),
2. A Study to Determine the Activity of SCH 717454 in
Subjects with Relapsed Osteosarcoma or Ewing’s Sarcoma (Study
P04720AM3) (now closed and not actively recruiting patients)
NCT00617890 (Phase II),
3. IMC-A12 in Combination with Temsirolimus (CCI-779) in
Patients With Advanced Cancers (Study is closed to Ewing’s
Sarcoma cohort) NCT00678769 (Phase I).
After initiation of an investigational therapy, patients were
evaluated clinically at 3- to 4-week intervals. At each visit, a history
was taken and physical examination performed along with
comprehensive metabolic and hematologic panels. Patients were
assessed for the onset of new symptoms and compliance with the
investigational therapy. Tumor response was determined using
Response Evaluation Criteria in Solid Tumors (RECIST) version
3.1 by positron emission tomography/computed tomography
(PET/CT) scans or CT scans obtained about every six to eight
weeks. Sections of original and recurrent tumor were available for
analysis. The morphoproteomic analysis reported in this manu-
script was not a part of the original Phase 1 trial protocols, and
were carried out as a separate subsequent analysis. Patient consent
and MD Anderson IRB approval were obtained for morphopro-
teomic analysis as outlined above.
Immunohistochemical and Morphoproteomic Analysis
Immunohistochemical (IHC) probes were used to detect the
following phosphorylated (p) antigens as published previously[16]:
p-mTOR (Ser 2448); p-Akt (Ser 473);and p-extracellular signal-
regulated kinase (ERK) 1/2 (Thr 202/Tyr204) [Cell Signaling
Technology, Beverly, MA]; and p-signal transducer and activator
of transcription (STAT)3 (Tyr 705) [Santa Cruz Biotechnology,
Santa Cruz, CA]. In addition, IHC probes in specimens from the
two patients were applied to detect the expressions of CD99
(DakoCytomation, Carpinteria, CA) and nestin (abcam, Cam-
bridge, MA). Chromogenic signals were evaluated by brightfield
microscopy and semi-quantified with regard to percentage of cells
stained (0–100%) and the staining intensity (0: non-staining, 1+:
weak staining, 2 +: moderate staining, and 3 +: strong staining).
Subcellular compartmentalizations were assessed as plasmalem-
mal, cytoplasmic, and/or nuclear. Concurrently run positive and
negative IHC controls reacted appropriately. The methods have
been published previously [7,9,16,17] and were performed in a
laboratory that is certified under the Clinical Laboratory
Improvement Amendments of 1988 (‘‘CLIA’’) as qualified to
perform high-complexity clinical testing.
Results
Patient outcomes with chemotherapy and targeted therapy are
summarized below.
Patient 1. A twenty-four year old Caucasian woman presented
with a three-year history of back pain and left lower extremity pain.
Magnetic resonance imaging (MRI) revealed a sacral mass, which
was determined to be Ewing’s sarcoma following pathological
assessment at MD Anderson. The tumor cells were positive for
CD99 and negative for chromogranin A, keratin and desmin. She
underwent six cycles of intravenous chemotherapy through central
line with vincristine (2 mg intravenous [IV]on day 1), adriamycin
(37.5 mg/m2/day IV for 2 days), and ifosfamide (2500 mg/m2 IV
for 4 days) with MESNA uroprotection, followed by resection of the
tumor, confirmed as being Ewing’s sarcoma. Fluorescent in situ
hybridrization showed a positive result for a clone with an EWSR1
gene rearrangement. The patient received postoperative radiation
therapy, followed by six cycles of adjuvant chemotherapy with
irinotecan. After six months of follow-up, lung metastases were
discovered. She was started on etoposide and after five months, her
tumors progressed. Liposomal doxorubicin(Doxil) wasinitiated, but
stopped after tumor progression. The patient then underwent
thoracotomy for removal of tumor, followed by erlotinib, followed
by another lung resection.
She was then referred to the Phase I clinic at MD Anderson
Cancer Center. A CT scan showed enlargement of numerous
Targeted Morphoproteomics of Ewing’s Sarcoma
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5.9 cm65.1 cm. She was treated on three sequential Phase I trials,
with continued disease progression. In December 2006, the patient
was started on a Phase I study of R1507 (Roche, Nutley NJ), a fully
human IgG1 type monoclonal antibody against IGF1R. Within six
weeks, she had a dramatic response, with near complete tumor
regression (Figure 1, previously described in [12]). No toxicity was
noted. After 20 months of continued treatment a small focus of
growing residual disease was found followed by surgical resection.
Therapy continued for another 15 months, followed by progressed
diseasein the patient’s lungs. Shewasstartedon another study using
a different anti-IGF1R antibody (IMC-A12; Imclone, San Diego
CA) [18] in combination with the mTOR inhibitor temsirolimus
(NCT00678769). She tolerated this combination without any major
side effects except a decrease in platelet counts. After 14 months of
treatment, both PET/CT and chest CT scans show no disease
(complete response) (Figure 2) and she continues on treatment.
Patient 2. A twenty-one year old Caucasian man presented
with back pain radiating to the left leg in December 2006. An
MRI revealed a large left iliac mass extending into the sacroiliac
joint. Biopsy showed Ewing’s sarcoma with a t(11;22)
translocation. On presentation he had a large left iliac primary
lesion and bilateral pulmonary nodules and no evidence of bone
marrow disease. He was enrolled on the Children’s Oncology
Group Study AEWS0031 (NCT00006734) and received standard
q 3 week regimen consisting of vincristine (2 mg/m2 IV push, on
day 1. maximum dose 2 mg.), doxorubicin(75 mg/m2/course
continuous IV infusion over 48 hours, beginning day 1),
cyclophosphamide (1200 mg/m2 IV infusion over 1 hour with
MESNA uroprotection, on day 1), alternating with ifosfamide
(1800 mg/m2/day IV infusion over 1 hour, Days 1–5 of each
cycle. (9,000 mg/m2 max total dose) and etoposide (100 mg/m2/
day IV infusion over 1 to 2 hours, days 1–5 of each cycle
(500 mg/m2 total dose). His pain improved after one treatment
and he had an excellent response. He then received 55.8 Gy
radiation in 31 fractions to the pelvis for local control of the
unresectable disease, as well as whole lung radiation therapy for
his pulmonary nodules at the end of chemotherapy. He completed
therapy with no evidence of disease. Eight months later he
developed recurrent pulmonary nodules. A PET/CT scan showed
activity only in lungs. He received topotecan and
cyclophosphamide, and although his tumors responded initially,
they eventually progressed. The patient then received
temozolomide and irinotecan, without response, followed by
enrollment on an IGF1R inhibitor study using SCH 717454
(Schering, Kenilworth NJ), an IGF1R antibody (19D12) [4,19].
He had near complete response (18 of 19 nodules improving or
disappeared) following 7 cycles. However, after 4 months, a
solitary left lung nodule began to grow, and he was taken off study
for progressive disease by RECIST. A thoracoscopic biopsy was
done and confirmed Ewing’s sarcoma. Subsequently, he was
started on etoposide, but disease continued to progress. He then
Figure 1. Imaging Responses in Ewing’s sarcoma patient 1. CT of the thorax in patient 1 with Ewing’s sarcoma response to IGF1R antibody
(R1507) alone [12]. Left panel shows pre-treatment CT scan of the thorax showing metastatic Ewing’s sarcoma in the lung. Right panel: Six weeks after
IGF1R antibody (R1507) therapy shows regression of tumor.
doi:10.1371/journal.pone.0018424.g001
Figure 2. Imaging Responses in Ewing’s sarcoma patient 1. CT of the thorax in patient 1 with Ewing’s sarcoma response to IGF1R antibody
(IMCA12)+ mTOR (Temsirolimus) combination. Left panel shows pre-treatment CT scan of the thorax showing metastatic Ewing’s sarcoma in the lung.
Right panel: Nine months after IGF1R antibody+ mTOR inhibitor (IMCA12+ Temsirolimus) therapy showing continued response.
doi:10.1371/journal.pone.0018424.g002
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the protocol of IMC-A12, IGF1R antibody in combination with
Temsirolimus, mTOR inhibitor (NCT00678769). Three out of
four nodules showed a near complete response and one nodule
remained stable. However, after four months, one nodule began to
grow, and he was removed from study (Figure 3). The non-
responding tumor was biopsied, and Ewing’s sarcoma was
confirmed. Subsequently, the patient was treated with high-dose
ifosfamide and also received proton radiation therapy to the lung
nodule.
Morphoproteomics /Correlative Studies
The pre-treatment similarities and differences between patient 1
and 2 are shown in Table 1.
Patient 1. A limited number of sections of metastatic tumor
from the following time points were available 1) before IGF1R
antibody therapy; and 2) from the resistant recurrence that emerged
during IGF1R antibody therapy (Figure 4). Constitutive mTOR
pathway activation was noted in the pre-anti-IGF1R specimen
(Figure 4) and reflected p-mTOR (Ser2448) expression in both
cytoplasmic plasmalemmal and nuclear compartments. Similar
findings have been reported in the Ewing’s family of tumors [16].
There was also cytoplasmic plasmalemmal expression of p-Akt
(Ser473), but with almost no nuclear expression, which was more
consistent with P13K/Akt/mTORC1 signaling pathway activity.
In contrast, there was apparent upregulation of these analytes in the
specimen from the IGF1R-resistant tumor that emerged during
IGF1R antibody therapy, with predominant nuclear expression of
both p-mTOR (Ser2448) and p-Akt (Ser473), consistent with
mTORC2 pathway activation [17,20,21]. In both biopsies, only
endothelial cells were immunopositive for nestin, a neural
precursor/differentiation marker, whereas the tumor cells were
immunonegative. Notably, p-STAT3(Tyr705) was detected in a
very minor component of the tumoral nuclei in the initial biopsy
and was variably expressed in the post-anti- IGF1R treatment
biopsy, ranging up to approximately one-half of the tumor cells in
one microanatomical region.
Patient 2. Sections of tumor before IGF1R antibody therapy
and after IGF1R antibody combined with mTOR inhibitor
therapy were available for analysis (Figure 5). A greater number of
sections were available than for patient 1, permitting more
extensive pathway evaluation (Figure 5).
There was constitutive activation of mTOR in the patient’s
original and recurrent tumor, evidenced by phosphorylation (p) of
mTOR in a putative site of activation, Ser2448, with a
predominantly nuclear distribution most likely indicating an
mTORC2 complex (rictor + p-mTOR), [20] and correlative
activation of Akt on Ser473 consistent with the presence of both
mTORC2 and dominant expression of p-Akt (Ser473) in tumoral
nuclei [17,20,21]. Constitutive activation of the Ras/Raf /ERK
pathway is noted in both specimens by p-ERK 1/2 (Thr202/
Tyr204) expression, showing nuclear translocation [9]. The
expression appeared generalized and uniform in recurrent tumor
and, to a lesser degree, in the original (primary) tumor. The signal
transducer and activator of transcription (STAT)3 pathway was
constitutively activated in both the primary and recurrent tumor,
as evidenced by expression with nuclear translocation of p-STAT3
(Tyr 705) in the vast majority of tumor cells. The neural and
endothelial precursor marker, nestin, was weakly expressed in the
original (primary) tumor (0–1+). However, in the recurrent tumor,
nestin was expressed in approximately 25% to 50% of tumor cells
(up to 3+ cytoplasmic plasmalemmal expression) (Figures 5 and 6).
Figure 3. Imaging Responses in Ewing’s sarcoma patient 2. FDG PET /CT in patient 2 with Ewing’s sarcoma response to IMCA12+Temsirolimus
combination and then emergence of resistance. Left panel shows pre-treatment FDG PET/CT scan of the thorax showing metastatic Ewing’s sarcoma
in the lung. Middle panel shows FDG PET/CT response after 8 weeks of treatment. Right panel shows re-emergence of resistance 16 weeks after IGF1R
antibody+ mTOR (IMCA12+ Temsirolimus) therapy.
doi:10.1371/journal.pone.0018424.g003
Table 1. Targeted Morphoproteomic Profiling of Ewing Sarcoma Patients Treated with Insulin-like Growth Factor-1 Receptor
(IGF-1R) Inhibitor: Pretreatment Specimens.
Ras/Raf kinase/Extracellular Signal-Regulated
Kinase (ERK) Pathway* mTORC2 Pathway* STAT3 Pathway Nestin
Patient No CD99 (Plasmalemmal) p-ERK K Thr 202/Tyr
204 [Nuclear]
p-Akt Ser 473
[Nuclear]
p-mTOR Ser2448[Nuclear]; p-STAT3** Tyr
705 [Nuclear]
(Cytoplasmic)
1 Present (1+) Present (1–3+) +/2 1+ ,10% 0
2 Present (2+) Present (0–3+)2 + 2+ .50% 1
*Maximum scoring intensity graded on a scale of 0 (no signal) to 3+ (high intensity).
**Percentage of positive tumoral nuclei.
doi:10.1371/journal.pone.0018424.t001
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expressed in recurrent tumor in the plasmalemmal and cytoplas-
mic compartments (not shown).
Discussion
There is no effective therapy for advanced Ewing’s sarcoma and
patients with advanced metastatic disease succumb to their disease.
Two patients with Ewing’s sarcoma who responded, but then
progressed after IGF1R inhibitor therapy alone showed consis-
tently high mTORC2 expression in their tumors. Both patients
responded after treatment to combined IGF1R and mTOR
inhibition. The time interval between the first and the second
IGF1R based therapy was 1 month for patient 1 and 4 months for
patient 2. One patient had a continued response and has remained
on IGF1R-based therapy for more than 50 months, the last 14
Figure 4. Schematic clinical history and immunohistochemistry of patient 1. Schematic history of patient 1 depicting time line of first
biopsy(Biopsy A) and second biopsy (Biopsy B). Immunohistochemistry Patient 1. Pre-IGF1R treatment (Specimen A) and Post –IGF1R treatment
(Specimen B) p-mTOR,p-AKT,p-STAT3 and nestin probes. Pre-treatment digital images (left hand frames, Specimen A) reveal: primarily cytoplasmic
and plasmalemmal expression of p-mTOR (Ser 2448) and p-Akt (Ser 473) consistent with preponderance of mTORC1 pathway; occasional p-STAT3
(Tyr 705) in tumoral nuclei (up to ,20%) and absence of cytoplasmic nestin. Post-treatment digital images (right hand frames, Specimen B) reveal:
primarily nuclear p-mTOR (Ser 2448) and p-Akt (Ser 473) consistent with mTORC2 pathway preponderance; moderate increase in number of tumor
cells with nuclear p-STAT3 (Tyr 705) (from 0 up to ,50% in some regions) and absence of cytoplasmic nestin (endothelial cells serve as internal
control). Original magnifications x400.
doi:10.1371/journal.pone.0018424.g004
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biopsy (Biopsy C) and second biopsy (Biopsy D). Immunohistochemistry Patient 2. Pre-IGF1R treatment (Specimen C) and Post –IGF1R+ mTOR
(Specimen D) p-mTOR,p-AKT,p-STAT3, nestin probes and p-ERK1/2. Pre-treatment digital images (left hand frames, Specimen C) reveal: primarily
cytoplasmic but with some nuclear expression of both p-mTOR (Ser 2448) and p-Akt (Ser 473) indicative of both mTORC1 and mTORC2 pathways;
nuclear p-STAT3 (Tyr 705) in the majority of tumoral nuclei and faint but detectable constitutive nestin expression. Post-treatment digital images
(right hand frames, Specimen D) reveal: preponderance of nuclear p-mTOR (Ser 2448) and p-Akt (Ser 473) consistent with upregulation of the
mTORC2 pathway; persistence of p-STAT3 (Tyr 705)expression in tumoral nuclei and an increase in cytoplasmic nestin expression, the latter consistent
with temsirolimus therapy. Constitutive activation of the Ras/Raf /ERK pathway is noted in both specimens by p-ERK 1/2 (Thr202/Tyr204) expression,
showing nuclear translocation. Original magnifications x400.
doi:10.1371/journal.pone.0018424.g005
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mTOR inhibitor. The patient’s last imaging scans showed no
disease. Unfortunately, the second patient acquired resistance.
Preclinical studies have shown that mTOR is a bypass pathway
for IGF1R targeting. Similarly, combined inhibition of IGF1R
and mTOR may circumvent counterproductive rapamycin-
induced upregulation of Akt that can occur within 6 hours of
treatment [3,22]. Several Phase I/II clinical trials are currently
investigating this potential synergy in advanced malignancies.
(Clinicaltrials.gov identifiers: NCT00678769; NCT00880282 and
NCT01016015).
In this context, our finding of upregulated p-Akt (Ser473) and p-
mTOR (Ser2448) in patient 1’s resistant tumor that emerged
following IGF1R antibody therapy is consistent with a resistance
mechanism that could be related to upregulation of TORC2. The
patient was, however, treated successfully with termsirolimus, a
TORC1 inhibitor. Although short-term inhibition of TORC1 drives
TORC2 formation and results in Akt activation, long-term TORC1
inhibition abrogates Akt expression through activation of S6K by
PKD1 and also blocks TORC2 assembly[23,24]. Activated S6K can
down-modulate Akt by acting against insulin receptor substrate 1
proteins and P13K [23]. Although these pathways have often been
depicted as linear, clearly there is a complex interplay among
signaling elements (Figure 7). EWS-FLI1 fusion protein, the hallmark
of Ewing’s sarcoma, downregulates insulin-like growth factor binding
protein 3, IGFBP3, and upregulates IGF-1 expression resulting in
enhanced IGF1R [25]. Therefore, treatment with an IGF1R
inhibitor may counteract EWS-FLI1-mediated upregulation of the
insulin receptor (IR) /IGF1R machinery. Temsirolimus is a
‘‘rapalog’’ and rapamycin has been shown to downregulate the
EWS-FLI1 fusion protein [26] possibly also lessening IR/IGF1R
signaling, and therefore providing an additional pathway by which
this molecule might be operative in this patient.
In patient 2, constitutive activation of Akt and mTOR is similar
to that in patient 1’s recurrent tumor, and is seen in baseline pre-
treatment tumor and in tumor that was resistant to IGF1R and
mTOR combination treatment. These observations suggest the
possibility that the TORC2 pathway has a role in primary and
recurrent tumor [17] (Figures 5, 6, and 7). After IGFR treatment
alone, response was followed by resistance. Similarly, an initial
response was followed by re-emergence of resistance following
treatment with the IGFR-mTOR inhibitor combination. The
mechanism of response to the IGFR and mTOR combination may
be similar to that in patient 1, that is, through Akt and mTOR
suppression that occurs with chronic temsirolimusexposure[23,24].
The biologic activity of the mTOR inhibitor temsirolimus is further
confirmed by the upregulation of nestin seen in the patient’s IGFR/
mTOR resistant tumor, since temsirolimus down-modulates EWS-
FLI1, which would be expected to upregulate nestin [26,27]
(Figure 7). However, other pathways are operative in this patient’s
tumor, including Ras/Raf /ERK and STAT3 (Figure 5).The
relative overexpression of CD99 in this patient is consistent with
activation of this pathway (not shown). In addition, p-Akt and S6K
are not downregulated by combined IGF1R and mTOR inhibition,
perhaps due to Ras/Raf/ERK activation. These signals might
account for tumor resistance [26]. Of interest, in addition to nestin
the patient’s recurrent tumor showed a propensity toward
differentiation along neural lines, as demonstrated by increased
expression of other neural markers such as CD56 or neural cell
adhesion molecule and synaptophysin.
We have demonstrated resistance/response mechanisms by
morphoproteomics in two patients with advanced Ewing’s
sarcoma. This needs to be analyzed retrospectively and validated
prospectively in a larger dataset to allow more robust conclusions.
Next generaration whole exome sequencing of patients with
Ewing’s sarcoma responding to IGF1R based treatment and
reverse phase protein array analysis in patients acquiring
resistance is underway and will help to decipher unidentified
mechanisms and perhaps unravel novel mutations and genetic
aberrations in the response and resistance pathways.
Our observations suggest that rational combinations of targeted
therapy, which modulate multiple relevant pathways, may be
useful in overcoming resistance in patients with Ewing’s sarcoma.
Inhibition of IGF1R and/or IGF1R and mTOR has resulted in
significant clinical activity in patients with Ewing’s sarcoma. Study
of an IGF1R inhibitor combined with mTOR inhibitor is
currently underway. Our pilot results suggests that morphopro-
teomic assessment of signaling pathway activation in Ewing’s
sarcoma merits further investigation as a guide to understanding
response and resistance signatures.
Figure 6. High magnification immunohistochemistry showing
nuclear versus cytoplasmic staining. Post-IGF1R+ mTOR inhibitor
therapy specimen from patient 2 in higher magnification (600X)
showing brown chromogenic signal in nestin with predominantly
cytoplasmic staining in the top panel and mTOR (Ser 2448) with
predominant nulclear staining in the bottom panel.
doi:10.1371/journal.pone.0018424.g006
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